Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series

BACKGROUND: It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment. METHODS: All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initia...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Carlino, Matteo S, Vanella, Vito, Girgis, Christina, Giannarelli, Diana, Guminski, Alex, Festino, Lucia, Kefford, Richard F, Menzies, Alexander M, Long, Georgina V, Ascierto, Paolo A
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2016
Предметы:
Short Communication
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5129828/
https://ncbi.nlm.nih.gov/pubmed/27711085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.321
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы